AARTIDRUGS vs SUNPHARMA: Stock Comparison

AARTI DRUGS vs SUN PHARMACEUTICAL IND LUpdated 4 Sept 26, 4:08 PM ISTNSE & company filings

SUN PHARMACEUTICAL IND L is the larger company by market capitalisation. AARTI DRUGS shows a lower P/E, a higher ROE and lower leverage, while SUN PHARMACEUTICAL IND L shows a higher dividend yield, faster revenue growth and a higher net margin. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

AARTIDRUGS leads 5; SUNPHARMA leads 8 of 13

Not a rating

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

AARTIDRUGSSUNPHARMA

Valuation lens

What price are you paying?

Market CapContext only
₹3,973 Cr
₹4.56 L Cr
P/E RatioAARTIDRUGS has the lower reading
20x
38.35x
P/B RatioAARTIDRUGS has the lower reading
2.47x
5.55x
EPSSUNPHARMA has the higher reading
₹5.57
₹50.42
Book ValueContext only
₹169.74
₹348.31
Dividend YieldSUNPHARMA has the higher reading
0.46%
0.83%

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

Market Cap
SUNPHARMA is the larger company
₹4.56 L Cr vs ₹3,973 Cr
P/E Ratio
AARTIDRUGS has a lower P/E
20x vs 38.35x
P/B Ratio
AARTIDRUGS has a lower P/B
2.47x vs 5.55x
EPS
SUNPHARMA has higher earnings per share
₹50.42 vs ₹5.57
Dividend Yield
SUNPHARMA has a higher dividend yield
0.83% vs 0.46%
Revenue Growth (TTM YoY)
SUNPHARMA has faster revenue growth
12.8% vs 6.4%
EPS Growth (TTM YoY)
SUNPHARMA has faster EPS growth
25.6% vs -12%
Qtr Sales Growth
SUNPHARMA has stronger quarterly sales growth
166.5% vs -10.72%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricAARTIDRUGSSUNPHARMA
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricAARTIDRUGSSUNPHARMA
Live Price₹431.65₹1,899
Day Change1.36%-0.89%
Volume2.5 L7.61 L
52-Week High₹534.55₹2,046.9
52-Week Low₹318.95₹1,548
Distance from 52W High-19.25%-7.23%

Valuation

MetricAARTIDRUGSSUNPHARMA
Market Cap₹3,973 Cr₹4.56 L Cr
P/E Ratio20x38.35x
P/B Ratio2.47x5.55x
EPS₹5.57₹50.42
Book Value₹169.74₹348.31
Dividend Yield0.46%0.83%

Growth

MetricAARTIDRUGSSUNPHARMA
Revenue Growth (TTM YoY)6.4%12.8%
EPS Growth (TTM YoY)-12%25.6%
Qtr Sales Growth-10.72%166.5%
Qtr Profit Growth1.44%160.17%

Profitability & Leverage

MetricAARTIDRUGSSUNPHARMA
ROE12.05%11.76%
ROCE10.64%9.6%
Net Margin7.6%18.56%
Operating Margin9.19%22.81%
Debt to Equity0.3x0.6x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricAARTIDRUGSSUNPHARMA
Promoter Holding54.43% 0.6 pp54.48%
FII Holding1.52% 0.06 pp14.53% 1.4 pp
DII Holding10.29% 0.07 pp22.18% 1.07 pp
Public Holding33.75% 0.57 pp8.81% 0.33 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: AARTI DRUGS and SUN PHARMACEUTICAL IND L.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.